COST

1,012.99

+0.12%↑

147.11

+0.4%↑

166.17

+0.9%↑

PEP

157.71

-0.33%↓

FMX

119.5

+1.82%↑

COST

1,012.99

+0.12%↑

147.11

+0.4%↑

166.17

+0.9%↑

PEP

157.71

-0.33%↓

FMX

119.5

+1.82%↑

COST

1,012.99

+0.12%↑

147.11

+0.4%↑

166.17

+0.9%↑

PEP

157.71

-0.33%↓

FMX

119.5

+1.82%↑

COST

1,012.99

+0.12%↑

147.11

+0.4%↑

166.17

+0.9%↑

PEP

157.71

-0.33%↓

FMX

119.5

+1.82%↑

COST

1,012.99

+0.12%↑

147.11

+0.4%↑

166.17

+0.9%↑

PEP

157.71

-0.33%↓

FMX

119.5

+1.82%↑

Strona główna・Stock List・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Open

SectorConsumer defensive

5.18 2.78

Buy Sell

Overview

Share price change

24h

Current

Min

4.95

Max

5.2

Key metrics
By Trading Economics
Income	-7.9M -10M
Sales	-5.3M 31M
Profit margin	-32.116
Employees	400

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+35.02% upside

Dividends
By Dow Jones
Next Earnings	10 cze 2026

Market Stats
By TradingEconomics
Market Cap	-81M 160M
Previous open	2.4
Previous close	5.18

News Sentiment

By Acuity

33%

67%

35 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 23:08 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 23:07 UTC

Earnings

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:20 UTC

Earnings

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 kwi 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 kwi 2026, 23:22 UTC

Earnings

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 kwi 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 kwi 2026, 22:52 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:33 UTC

Earnings

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 kwi 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 kwi 2026, 22:05 UTC

Earnings

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 21:57 UTC

Earnings

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 kwi 2026, 21:55 UTC

Earnings

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 kwi 2026, 21:53 UTC

Earnings

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Price Target

By TipRanks

35.02% upside

12 Months Forecast

Average 6.67 USD 35.02%

High 9 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forLifecore Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Lifecore Biomedical Inc - Dist in the past 3 months.

Sentiment

By Acuity

35 / 131 Ranking in Consumer defensive

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.